Harmony Biosciences (HRMY) to Release Quarterly Earnings on Tuesday

Harmony Biosciences (NASDAQ:HRMY) will likely be posting its quarterly earnings results before the market opens on Tuesday, February 25th. Analysts expect Harmony Biosciences to post earnings of $0.74 per share and revenue of $201.25 million for the quarter. Individual that are interested in registering for the company’s earnings conference call can do so using this link.

Harmony Biosciences Price Performance

HRMY stock opened at $34.56 on Friday. The stock has a 50-day moving average price of $36.57 and a two-hundred day moving average price of $35.79. The stock has a market cap of $1.97 billion, a PE ratio of 16.38, a price-to-earnings-growth ratio of 0.47 and a beta of 0.80. The company has a current ratio of 3.24, a quick ratio of 3.20 and a debt-to-equity ratio of 0.28. Harmony Biosciences has a 1 year low of $28.14 and a 1 year high of $41.61.

Wall Street Analyst Weigh In

HRMY has been the subject of a number of research analyst reports. Cantor Fitzgerald lifted their price target on Harmony Biosciences from $51.00 to $58.00 and gave the stock an “overweight” rating in a report on Wednesday, October 30th. Deutsche Bank Aktiengesellschaft started coverage on shares of Harmony Biosciences in a research note on Tuesday, February 11th. They issued a “buy” rating and a $55.00 price objective on the stock. HC Wainwright reissued a “buy” rating and issued a $75.00 price objective on shares of Harmony Biosciences in a research note on Wednesday. Oppenheimer reaffirmed an “outperform” rating and set a $59.00 target price (up previously from $56.00) on shares of Harmony Biosciences in a research note on Wednesday, October 30th. Finally, Needham & Company LLC reduced their price objective on shares of Harmony Biosciences from $52.00 to $50.00 and set a “buy” rating on the stock in a research note on Wednesday. Nine investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $53.67.

Insider Transactions at Harmony Biosciences

In other news, CEO Jeffrey M. Dayno sold 19,293 shares of the stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $40.13, for a total value of $774,228.09. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Jeffrey Dierks sold 10,507 shares of the company’s stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $37.01, for a total transaction of $388,864.07. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 72,452 shares of company stock worth $2,831,679. Corporate insiders own 30.80% of the company’s stock.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.